The <i>in vitro</i> metabolism and <i>in vivo</i> pharmacokinetics of the bacterial β-glucuronidase inhibitor UNC10201652-Reference-Cited by-同舟云学术

The in vitro metabolism and in vivo pharmacokinetics of the bacterial β-glucuronidase inhibitor UNC10201652

Published:2022-08-03 Issue:8 Volume:52 Page:904-915
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Kerins Anna¹^ORCID,Koszyczarek Marta¹^ORCID,Smith Caroline¹,Butler Phil¹^ORCID,Riley Rob¹,Madgula Vamsi²,Naik Nilkanth²,Redinbo Matthew R.³^ORCID,Wilson Ian D.⁴^ORCID

Affiliation:

1. Cyprotex Discovery, Macclesfield, UK

2. DMPK and Toxicology, Sai Life Sciences Limited, Hyderabad, India

3. Departments of Chemistry, Biochemistry & Biophysics, and Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

4. Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College, London, UK

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2022.2128468

Reference16 articles.

1. Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory Drugs

2. Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy

3. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans

4. NSAID Acyl Glucuronides and Enteropathy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro and in vivo studies on the metabolism and pharmacokinetics of the selective gut microbial β-glucuronidase targeting compound Inh 1;Xenobiotica;2024-06-12

2. Bioactivation and reactivity research advances – 2022 year in review‡;Drug Metabolism Reviews;2023-08-22